To examine the effects of antilipemic agents on the glomerular filtration rate (GFR) and proteinuria or albuminuria, in patients with renal disease.
The categories of data extracted included: author and year of study; study design; the number and age of participants; the gender of participants; study duration; cause of renal disease, i.e. diabetes, glomerulonephritis, or other/unknown; treatment; the end point studied, i.e. GFR or proteinuria; the baseline GFR and cholesterol level in the treatment and control groups; and the change in serum cholesterol and blood-pressure in the treatment and control groups.
Methods of synthesis
How were the studies combined? Weighted means and confidence intervals (CIs) were calculated for the combined differences between the treatment and control groups using a fixed-effect model. The results of the trials were also combined using a random-effects model, as described by DerSimonian and Laird (see Other Publications of Related Interest no.1). Publication bias was assessed using a funnel plot.
How were differences between studies investigated?
Differences between studies were investigated using the chi-squared test for heterogeneity. Heterogeneity between trials was also investigated using a L'Abbe plot (see Other Publications of Related Interest no.2).
Results of the review
Thirteen studies (n=404) met the inclusion criteria: 10 RCTs (n=347), 2 randomised crossover trials (n=40), and 1 controlled trial (n=17) in which participants were alternately allocated to the treatment and control groups.
GFR (12 studies): 94% (362 of 384) of the patients completed the follow-up. Using the fixed-effect model, the mean weighted effect of lipid-lowering treatment on the change in GFR was 0.156 mL/minute per month (95% CI: 0.026, 0.285, p=0.008). This indicated that treatment with lipid-reducing agents had a favourable effect on GFR. The combined treatment effect and CIs were the same for the random-effects model. In addition, removing the trial that was not truly random had no effect on the result: the effect of treatment remained at 0.156 mL/minute per month (95% CI: 0.025, 0.289, p=0.008).
A chi-squared test for heterogeneity between the studies was not statistically significant. A L'Abbe plot failed to reveal any marked heterogeneity between the trials.
A funnel plot failed to suggest that there was publication bias.
The regression analysis showed no correlation between the effects of treatment on GFR and study quality, the percentage change in cholesterol, the type of lipid-lowering agent, or the cause of renal disease. However, there was a correlation shown between longer follow-up and the effect of treatment on GFR improvement (p=0.007).
Proteinuria (11 studies): 94% (246 of 262) of the patients completed the follow-up. Using the fixed-effect model, the mean weighted effect of treatment on the change in urine protein or albumin excretion was -0.283 (95% CI: -0.427, -0.139, p<0.001). The results were not statistically significant when using the random-effects method: the mean weighted mean was -0.249 (95% CI: -0.562, +0.064, p=0.077).
A chi-squared test for heterogeneity between the studies was statistically significant (p<0.001), thus questioning the validity of combining the results. A subsequent regression analysis to investigate the differences between study results found no obvious explanation for this heterogeneity.
Quality assessment.
Of the included trials, 10 were randomised and controlled, 1 assigned every other patient to the treatment or control groups, and 2 used a randomised crossover design. The masking of the investigators and participants varied across the trials: both the investigators and the participants were masked in 6 trials; neither the investigators nor the participants were masked in 4 trials; in 1 trial, the participants but not the investigators were masked; and in 2 trials, the information on masking was unavailable.
